Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 19/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 15/20 | 0.81 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.80 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.80 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.80 |
| ▸ | FLT3 | P36888 | 1/20 | 0.80 |
| ▸ | BLK | P51451 | 1/20 | 0.80 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.80 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.80 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23327317 | 0.93 | CHEK1 (0.81) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL19208028 | 0.93 | CHEK1 (0.81) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL19208011 | 0.92 | CHEK1 (0.80) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL19208012 | 0.92 | CHEK1 (0.80) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL30675397 | 0.92 | CHEK1 (0.80) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL19208010 | 0.90 | CHEK1 (0.82) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL29632362 | 0.90 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL24936243 | 0.90 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL30517001 | 0.89 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL30528862 | 0.89 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3411036-B1 | 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS | PHARMAENGINE INC (TW) | 2021-12-29 | — | — | EP | claimed |
| US-11116767-B2 | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (Chk1) inhibitors, and their preparations and applications | PHARMAENGINE, INC. (TW) | 2021-09-14 | — | — | US | claimed |
| US-20210137918-A1 | 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS | PHARMAENGINE, INC. (TW) | 2021-05-13 | — | — | US | claimed |
| EP-3411036-A1 | 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS | Pharmaengine, Inc. (TW) | 2018-12-12 | — | — | EP | claimed |
| WO-2017132928-A1 | 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS | PHARMAENGINE, INC. (CN) | 2017-08-10 | — | — | WO | claimed |
| EP-3411036-B1 | 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS | PHARMAENGINE INC (TW) | 2021-12-29 | — | — | EP | disclosed |
| US-11116767-B2 | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (Chk1) inhibitors, and their preparations and applications | PHARMAENGINE, INC. (TW) | 2021-09-14 | — | — | US | disclosed |
| US-20210137918-A1 | 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS | PHARMAENGINE, INC. (TW) | 2021-05-13 | — | — | US | disclosed |
| EP-3411036-A1 | 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS | Pharmaengine, Inc. (TW) | 2018-12-12 | — | — | EP | disclosed |
| WO-2017132928-A1 | 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS | PHARMAENGINE, INC. (CN) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137918-A1 | 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS | CHEK1, CHEK2, BUB1 | CHEK1 1/4885KCNH2 2305/4885NUAK1 137/4885 |
| US-11116767-B2 | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (Chk1) inhibitors, and their preparations and applications | CHEK1, CHEK2, BUB1 | CHEK1 1/4885KCNH2 2305/4885NUAK1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.